Gaining Mechanistic Insight Into Coproporphyrin I as Endogenous Biomarker for OATP1B‐Mediated Drug–Drug Interactions Using Population Pharmacokinetic Modeling and Simulation
Citations Over TimeTop 10% of 2017 papers
Abstract
This study evaluated coproporphyrin I (CPI) as a selective endogenous biomarker of OATP1B-mediated drug-drug interactions (DDIs) relative to clinical probe rosuvastatin using nonlinear mixed-effect modeling. Plasma and urine CPI data in the presence/absence of rifampicin were modeled to describe CPI synthesis, elimination clearances, and obtain rifampicin in vivo OATP Ki. The biomarker showed stable interoccasion baseline concentrations and low interindividual variability (85%). Estimated rifampicin in vivo unbound OATP Ki (0.13 μM) using CPI data was 2-fold lower relative to rosuvastatin. Model-based simulations and power calculations confirmed sensitivity of CPI to identify moderate and weak OATP1B inhibitors in an adequately powered clinical study. Current analysis provides the most detailed evaluation of CPI as an endogenous OATP1B biomarker to support optimal DDI study design; further pharmacogenomic and DDI data with a panel of inhibitors are required.
Related Papers
- → Rosuvastatin: a new inhibitor of HMG-CoA reductase for the treatment of dyslipidemia(2003)119 cited
- → Benefits of Rosuvastatin in Cardiovascular Protection Remain Unclear After HOPE-3(2016)3 cited
- [Clinical trials with rosuvastatin: efficacy and safety of its use].(2003)
- Rosuvastatin: do we need another statin?(2001)
- Clinical efficacy of rosuvastatin in lipid management in Chinese patients in Hong Kong(2009)